- Home
- SPRO vs BHM Comparison
SPRO vs BHM Comparison
Compare SPRO & BHM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRO
- BHM
- Stock Information
- Founded
- SPRO 2013
- BHM 2022
- Country
- SPRO United States
- BHM United States
- Employees
- SPRO N/A
- BHM N/A
- Industry
- SPRO Biotechnology: Pharmaceutical Preparations
- BHM Real Estate Investment Trusts
- Sector
- SPRO Health Care
- BHM Real Estate
- Exchange
- SPRO Nasdaq
- BHM Nasdaq
- Market Cap
- SPRO 62.7M
- BHM 57.9M
- IPO Year
- SPRO 2017
- BHM N/A
- Fundamental
- Price
- SPRO $1.17
- BHM $13.96
- Analyst Decision
- SPRO Buy
- BHM
- Analyst Count
- SPRO 3
- BHM 0
- Target Price
- SPRO $5.00
- BHM N/A
- AVG Volume (30 Days)
- SPRO 470.6K
- BHM 2.3K
- Earning Date
- SPRO 11-14-2024
- BHM 01-01-0001
- Dividend Yield
- SPRO N/A
- BHM N/A
- EPS Growth
- SPRO N/A
- BHM N/A
- EPS
- SPRO 0.06
- BHM N/A
- Revenue
- SPRO $106,455,000.00
- BHM $58,198,000.00
- Revenue This Year
- SPRO N/A
- BHM N/A
- Revenue Next Year
- SPRO N/A
- BHM N/A
- P/E Ratio
- SPRO $17.92
- BHM N/A
- Revenue Growth
- SPRO 37.01
- BHM 35.82
- 52 Week Low
- SPRO $1.01
- BHM $13.25
- 52 Week High
- SPRO $1.89
- BHM $19.01
- Technical
- Relative Strength Index (RSI)
- SPRO 41.49
- BHM 39.10
- Support Level
- SPRO $1.28
- BHM $13.89
- Resistance Level
- SPRO $1.22
- BHM $14.43
- Average True Range (ATR)
- SPRO 0.07
- BHM 0.29
- MACD
- SPRO -0.01
- BHM 0.02
- Stochastic Oscillator
- SPRO 32.73
- BHM 12.66
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About BHM Bluerock Homes Trust Inc.
Bluerock Homes Trust Inc owns and operates single-family properties that generate rental and other property-related income through the leasing of units to a diverse base of tenants. The properties are located in Sunbelt and the Western United States.